S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:NVCR

NovoCure (NVCR) Stock Price, News & Analysis

$16.43
+0.18 (+1.11%)
(As of 03/4/2024 ET)
Today's Range
$15.88
$16.58
50-Day Range
$12.42
$16.30
52-Week Range
$10.87
$83.60
Volume
699,195 shs
Average Volume
1.29 million shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00

NovoCure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
131.3% Upside
$38.00 Price Target
Short Interest
Bearish
6.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.65mentions of NovoCure in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$33,539 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.74) to ($1.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.54 out of 5 stars

Medical Sector

294th out of 948 stocks

Surgical & Medical Instruments Industry

36th out of 96 stocks


NVCR stock logo

About NovoCure Stock (NASDAQ:NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Stock Price History

NVCR Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
NovoCure Stock (NASDAQ:NVCR), Short Interest Report
NovoCure: Q4 Earnings Snapshot
Here's what Wall Street expects from NovoCure's earnings
NovoCure Q4 2023 Earnings Preview
NovoCure: Stay Cautious Amid Positive Signs
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/04/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,453
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.00
High Stock Price Target
$51.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+131.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-207,040,000.00
Pretax Margin
-37.65%

Debt

Sales & Book Value

Annual Sales
$509.34 million
Book Value
$3.39 per share

Miscellaneous

Free Float
101,021,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
0.41
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














NVCR Stock Analysis - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price target for 2024?

9 analysts have issued 1-year target prices for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they expect the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2024?

NovoCure's stock was trading at $14.93 at the beginning of 2024. Since then, NVCR shares have increased by 10.0% and is now trading at $16.43.
View the best growth stocks for 2024 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.08. The medical equipment provider earned $133.80 million during the quarter, compared to the consensus estimate of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative trailing twelve-month return on equity of 51.63%. NovoCure's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.36) EPS.

What guidance has NovoCure issued on next quarter's earnings?

NovoCure issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $133.8 million-$133.8 million, compared to the consensus revenue estimate of $129.3 million.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.13%), Capital International Investors (8.29%), Baillie Gifford & Co. (4.53%), Capital World Investors (3.07%), Price T Rowe Associates Inc. MD (2.11%) and Price T Rowe Associates Inc. MD (2.11%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCR) was last updated on 3/4/2024 by MarketBeat.com Staff